AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21607190 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel
Number of subjects: 30
Study 21607562 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical muscle stimulation (2 sessions/day during hospitalization, 15 ± 1 training sessions)
Number of subjects: 19
Study 21607774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rate balloon brachytherapy (HDRBB) delivering 34 Gy in 10 fractions
Number of subjects: 8
Study 21607774 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal external beam irradiation (3D-CRT) consisting of 38.5 Gy in 10 fractions
Number of subjects: 8
Study 21607774 — intervention group
Group type: EXPERIMENTAL
Intervention: Local toxicity assessment
Number of subjects: 8
Study 21609134 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV1-CB-hAAT administered by intramuscular injection at doses of 6.0×10(11), 1.9×10(12), and 6.0×10(12) vector genomes/kg (n=3 subjects/dose)
Number of subjects: 9
Study 21609134 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV1-CB-hAAT
Number of subjects: 9
Study 21610204 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2042
Study 21611722 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tomographic cisternography (CTC)
Number of subjects: 70
Study 21611722 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt insertion
Number of subjects: 70
Study 21611722 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative iNPH grading scale-R scores
Number of subjects: 70
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Research Arm Test
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Assessment for Upper Extremity
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic analysis of arm movements (computer-based objective methods)
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: ABILHAND questionnaire of manual ability
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Spasticity
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive range of motion
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on Participation and Autonomy
Number of subjects: 120
Study 21612620 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol Quality of Life Scale
Number of subjects: 120
Study 21612646 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 23 mg/d
Number of subjects: 1434
Study 21612646 — intervention group
Group type: COMPARATOR
Intervention: donepezil 10 mg/d
Number of subjects: 1434
Study 21612781 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-EPI equation
Number of subjects: 15773
Study 21612781 — intervention group
Group type: COMPARATOR
Intervention: MDRD Study equation
Number of subjects: 15773
Study 21612836 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010, capsaicin 8% patch
Number of subjects: 117
Study 21613261 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine delivered at 20 mg/m² by 1-hour infusion (Arm A) for 3, 5, or 7 days before standard induction chemotherapy.
Number of subjects: 27
Study 21613261 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine delivered at 20 mg/m² by continuous infusion (Arm B) for 3, 5, or 7 days before standard induction chemotherapy.
Number of subjects: 27
Study 21613261 — intervention group
Group type: COMPARATOR
Intervention: Standard induction chemotherapy with infusional cytarabine (100 mg/m² for 7 days) and daunorubicin (60 mg/m² × 3 doses).
Number of subjects: 27
Study 21613319 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum carotid intima-media thickness (CIMT) measurement
Number of subjects: 3364
Study 21613559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverages
Number of subjects: 0
Study 21613559 — intervention group
Group type: COMPARATOR
Intervention: Glucose-sweetened beverages
Number of subjects: 0
Study 21617560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel Habit Questionnaire (BHQ)
Number of subjects: 416
Study 21619642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination in Paarl
Number of subjects: 1137
Study 21619642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination in Rietvlei
Number of subjects: 1137
Study 21619642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination in Umlazi
Number of subjects: 1137
Study 21619642 — intervention group
Group type: COMPARATOR
Intervention: Incomplete vaccination in Rietvlei compared to Paarl
Number of subjects: 1137
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fara'd dates (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lulu dates (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bo ma'an dates (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabbas dates (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Khalas dates (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fara'd dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lulu dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bo ma'an dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabbas dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: EXPERIMENTAL
Intervention: Khalas dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Number of subjects: 23
Study 21619670 — intervention group
Group type: COMPARATOR
Intervention: Glucose (50 g)
Number of subjects: 23
Study 21619692 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nuts (BNG), n = 8, 15-25 g/day (equivalent to 3 to 5 units/day)
Number of subjects: 17
Study 21619692 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nuts (BNG)
Number of subjects: 17
Study 21619692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG, lactose), n = 9, one capsule/day
Number of subjects: 17
Study 21620357 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 123
Study 21620511 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate plus topotecan
Number of subjects: 9
Study 21620645 — intervention group
Group type: EXPERIMENTAL
Intervention: Victoria Bowel Performance Scale (BPS)
Number of subjects: 192
Study 21620645 — intervention group
Group type: COMPARATOR
Intervention: Control group (new nursing assessment tools)
Number of subjects: 192
Study 21621166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 21
Study 21621166 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 21
Study 21621668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone instability test (PIT) performed by examiners
Number of subjects: 30
Study 21622693 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 µg)
Number of subjects: 682
Study 21623265 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (PF02341066), a dual MET and ALK inhibitor; specific dosage and duration not mentioned.
Number of subjects: 1
Study 21623649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 (9 μg daily)
Number of subjects: 44
Study 21623649 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 injections
Number of subjects: 44
Study 21623761 — intervention group
Group type: EXPERIMENTAL
Intervention: AICDA expression
Number of subjects: 0
Study 21623761 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length isoform AICDA
Number of subjects: 0
Study 21624046 — intervention group
Group type: EXPERIMENTAL
Intervention: High PAI-1 activity (≥ 75th percentile)
Number of subjects: 199
Study 21624046 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of t-PA antigen (≥ 75th percentile)
Number of subjects: 199
Study 21624046 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in levels of F(1+2)
Number of subjects: 199
Study 21626286 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography screening for obstructive sleep apnea (OSA)
Number of subjects: 132
Study 21626286 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography screening for OSA
Number of subjects: 132
Study 21627839 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus celecoxib (400 mg/day)
Number of subjects: 45
Study 21627839 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus celecoxib
Number of subjects: 45
Study 21628633 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation (500 μg/d) for 3 years
Number of subjects: 438
Study 21628633 — intervention group
Group type: COMPARATOR
Intervention: No phylloquinone supplementation
Number of subjects: 438
Study 21628633 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone-supplemented group
Number of subjects: 438
Study 21628721 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype
Number of subjects: 1069
Study 21628721 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype with clinical variables
Number of subjects: 1069
Study 21630308 — intervention group
Group type: EXPERIMENTAL
Intervention: CRd (cyclophosphamide, lenalidomide, and dexamethasone)
Number of subjects: 53
Study 21630312 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory and echocardiography markers
Number of subjects: 0
Study 21631213 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 27
Study 21631321 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI) in subjects with traumatic brain injury
Number of subjects: 63
Study 21631321 — intervention group
Group type: COMPARATOR
Intervention: Diffusion Tensor Imaging (DTI) in controls (21 military personnel with blast exposure but no clinical diagnosis of traumatic brain injury)
Number of subjects: 63
Study 21631321 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up DTI scans in subjects with traumatic brain injury
Number of subjects: 63
Study 21631321 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI findings in subjects with traumatic brain injury
Number of subjects: 63
Study 21632834 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic continuous positive airway pressure devices
Number of subjects: 0
Study 21632852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (given intravenously every two weeks until disease progression)
Number of subjects: 0
Study 21632852 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 0
Study 21632855 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial TIL outgrowth
Number of subjects: 226
Study 21632855 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≤30 years
Number of subjects: 226
Study 21632855 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 226
Study 21632855 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy 30 days before tumor harvest
Number of subjects: 226
Study 21632855 — intervention group
Group type: COMPARATOR
Intervention: Biochemotherapy within 0 to 60 days of tumor harvest
Number of subjects: 226
Study 21633906 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (a 26S proteasome inhibitor)
Number of subjects: 0
Study 21635145 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment in healthy volunteers
Number of subjects: 0
Study 21636665 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with COPD experiencing exacerbations
Number of subjects: 1273
Study 21636665 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with COPD experiencing hospitalized exacerbations
Number of subjects: 1273
Study 21636665 — intervention group
Group type: COMPARATOR
Intervention: African American patients with COPD without exacerbations
Number of subjects: 1273
Study 21636665 — intervention group
Group type: COMPARATOR
Intervention: Caucasian patients with COPD without exacerbations
Number of subjects: 1273
Study 21636665 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with COPD
Number of subjects: 1273
Study 21636665 — intervention group
Group type: COMPARATOR
Intervention: Caucasian patients with COPD
Number of subjects: 1273
Study 21638133 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected type 2 diabetes
Number of subjects: 6041
Study 21638133 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose regulation (IGR)
Number of subjects: 6041
Study 21638133 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed glucose disorders
Number of subjects: 6041
Study 21638133 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asian population
Number of subjects: 6041
Study 21639407 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg, uptitrated to OM 40 mg, followed by hydrochlorothiazide (HCTZ) 12.5-25 mg at 3-week intervals
Number of subjects: 178
Study 21639874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg daily
Number of subjects: 0
Study 21639874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21639874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin with >/= 50% pain improvement
Number of subjects: 0
Study 21639874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin with pain score <30 mm on VAS
Number of subjects: 0
Study 21639874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin with both >/= 50% pain improvement and pain score <30 mm on VAS
Number of subjects: 0
Study 21642245 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vector encoding human IFN-α (Ad.IFN-α2b) administered intrapleurally, two doses.
Number of subjects: 9
Study 21642514 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant trabectedin (1.5 mg/m(2) 24-h i.v. infusion every 3 weeks; three to six cycles)
Number of subjects: 23
Study 21642685 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate, 400 mg orally twice daily
Number of subjects: 28
Study 21645184 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/24 h)
Number of subjects: 208
Study 21645184 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch
Number of subjects: 208
Study 21645894 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21646032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride (Kuvan®) at a mean dose of 16.2±4.7 mg/kg/day for an average exposure of 658.7±221.3 days.
Number of subjects: 111
Study 21646941 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaporative skin cooling devices at 30°C
Number of subjects: 13
Study 21646941 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercise on a bicycle ergometer at ambient temperatures of 25 and 30°C without cooling
Number of subjects: 13
Study 21646941 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercise on a bicycle ergometer at ambient temperatures of 25 and 30°C
Number of subjects: 13
Study 21648278 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 7998
Study 21648278 — intervention group
Group type: COMPARATOR
Intervention: Obese boys
Number of subjects: 7998
Study 21648278 — intervention group
Group type: COMPARATOR
Intervention: Obese girls
Number of subjects: 7998
Study 21648284 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) stimulation testing with arginine and GH releasing hormone
Number of subjects: 10
Study 21649541 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (250 mg twice daily)
Number of subjects: 25
Study 21649849 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of stored platelets
Number of subjects: 0
Study 21651873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispebjerg Early Warning Score (BEWS) ≥ 5
Number of subjects: 300
Study 21651873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispebjerg Early Warning Score (BEWS)
Number of subjects: 300
Study 21652249 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean mass measurement
Number of subjects: 134
Study 21652249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass measurement in women
Number of subjects: 134
Study 21653528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (ART)
Number of subjects: 0
Study 21653528 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV) Study
Number of subjects: 0
Study 21653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent comprehension quiz
Number of subjects: 525
Study 21653689 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (125 mg/m²/day for children, 90 mg/m²/day for adults)
Number of subjects: 88
Study 21653689 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 88
Study 21653800 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat consumption (highest quintile)
Number of subjects: 40291
Study 21653800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh red meat consumption (highest quintile)
Number of subjects: 40291
Study 21657861 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone (0.15 mg/kg initial dose, adjusted to 0.3 mg/kg or 0.075 mg/kg as needed, maximum one dose per 24 hours)
Number of subjects: 82
Study 21657861 — intervention group
Group type: COMPARATOR
Intervention: DB placebo
Number of subjects: 82
Study 21658885 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting self-expanding nitinol stent
Number of subjects: 104
Study 21659356 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan (3×14 g/m²) and Fludarabine (5×30 mg/m²)
Number of subjects: 45
Study 21659356 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan and Fludarabine
Number of subjects: 45
Study 21659363 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m(2)/day intravenously over one hour for five consecutive days every four weeks
Number of subjects: 101
Study 21659363 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine treatment
Number of subjects: 101
Study 21659625 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-mechanistic nonlinear disease progression model using covariates
Number of subjects: 191
Study 21659625 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariates affecting baseline disease status
Number of subjects: 191
Study 21659625 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariates influencing disease progression rate
Number of subjects: 191
Study 21659625 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of disease progression rates
Number of subjects: 191
Study 21659657 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 single-nucleotide polymorphisms (SNPs) in or near 17 genes in 11 previously identified genome-wide significant (GWS) spirometric genomic regions.
Number of subjects: 5456
Study 21659657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense panel of imputed HapMap2 SNP markers from the 17 genes located near the 32 GWS SNPs and in a set of 21 well-studied COPD candidate genes.
Number of subjects: 5456
Study 21663862 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly topotecan (6 mg/m(2) I.V. for 6 weeks)
Number of subjects: 38
Study 21664205 — intervention group
Group type: EXPERIMENTAL
Intervention: Free flap skin temperature assessment using a digital infrared surface thermometer (Medisana FTD, Germany)
Number of subjects: 54
Study 21664205 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory assessment using Laser-Doppler and photospectrometry (Oxygen-to-see, Lea Medizintechnik, Germany)
Number of subjects: 54
Study 21664608 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (bipolar patients)
Number of subjects: 102
Study 21664608 — intervention group
Group type: COMPARATOR
Intervention: Lifetime history of alcohol dependence/abuse
Number of subjects: 102
Study 21664608 — intervention group
Group type: COMPARATOR
Intervention: History of drug use
Number of subjects: 102
Study 21664608 — intervention group
Group type: COMPARATOR
Intervention: Age of illness onset
Number of subjects: 102
Study 21666249 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary N-acetyl-beta-D-glucosaminidase (NAG)
Number of subjects: 2130
Study 21666249 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney injury molecule 1 (KIM-1)
Number of subjects: 2130
Study 21666249 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL)
Number of subjects: 2130
Study 21666249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of impaired eGFR, increased UACR, and high NAG
Number of subjects: 2130
Study 21667134 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative S-1 (80 mg/m²/day, days 1-21) plus cisplatin (60 mg/m² on day 8) for 2 courses followed by radical gastrectomy and postoperative S-1 (80 mg/m²/day, days 1-14) every 3 weeks for 1 year
Number of subjects: 51
Study 21667134 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection
Number of subjects: 51
Study 21667134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Cy1 alone
Number of subjects: 51
Study 21668743 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophizing
Number of subjects: 123
Study 21668743 — intervention group
Group type: EXPERIMENTAL
Intervention: State anxiety
Number of subjects: 123